This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aoyagi, K.
Right arrow Articles by Yagi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aoyagi, K.
Right arrow Articles by Yagi, S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 1999, p. 1802-1808, Vol. 37, No. 6
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Development of a Simple and Highly Sensitive Enzyme Immunoassay for Hepatitis C Virus Core Antigen

Katsumi Aoyagi,1,* Chiharu Ohue,1 Kumiko Iida,1 Tatsuji Kimura,1 Eiji Tanaka,2 Kendo Kiyosawa,2 and Shintaro Yagi1

Diagnostic Division, Tonen Corporation, Ohi-Machi, Iruma-Gun, Saitama 356-8505,1 and Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Nagano 390-8621,2 Japan

Received 6 October 1998/Returned for modification 19 November 1998/Accepted 16 March 1999

A highly sensitive enzyme immunoassay (EIA) for the hepatitis C virus (HCV) core antigen (HCVcAg) was developed, and its performance was compared with that of the AMPLICOR HCV test (Roche Molecular Systems). The developed one-step pretreatment method, 30-min incubation of the specimen with a solution containing three different types of detergents (Triton X-100, 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate [CHAPS], and sodium dodecyl sulfate), does not require any special device. Because the interfering anti-core antibody in the sample was sufficiently inactivated by the pretreatment, HCVcAg in the sample could be detected. The immunoreactivity on gel filtration was shifted from void fractions to those corresponding to the molecular mass range from 20 to 25 kDa, which is equal to the estimated molecular mass of HCVcAg, after the pretreatment. By the recovery test with HCVcAg-positive serum, the recovery rate was 93.5 to 106.5%. There was no interference with the EIA by anticoagulants or blood components in the serum. When the cutoff value was tentatively set at 0.5 mU/ml based on the distribution of healthy subjects' sera, the sera of all healthy subjects (n = 125) and patients with hepatitis B (n = 50) were negative. HCVcAg was detected in sera from 57 of 73 individuals (78.1%) with anti-HCV antibody. Similarly, HCV RNA was detected in sera from 59 individuals (80.8%) with the AMPLICOR HCV as the qualitative test (AMPLICOR HCV test) and in sera from 54 individuals (74.0%) by the AMPLICOR HCV Monitor as the quantitative test (AMPLICOR Monitor test). Concentrations of HCVcAg and HCV RNA (measured by the AMPLICOR Monitor test) correlated significantly (r = 0.8, P < 0.001). On seroconversion panels, HCVcAg was detected during the early stage of infection, when anti-HCV antibodies had not been produced. This assay for HCVcAg is simpler than assays for HCV RNA based on gene technology and shows specificity and sensitivity equivalent to those of the AMPLICOR HCV test.


* Corresponding author. Mailing address: Diagnostic Division, Tonen Corporation, 1-3-1 Nishi-tsurugaoka, Ohi-Machi, Iruma-Gun, Saitama 356-8505, Japan. Phone: 81 492-66-8327. Fax: 81 492-66-8385. E-mail: katsumi.aoyagi{at}tonen.co.jp.


Journal of Clinical Microbiology, June 1999, p. 1802-1808, Vol. 37, No. 6
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Saeed, M., Suzuki, R., Kondo, M., Aizaki, H., Kato, T., Mizuochi, T., Wakita, T., Watanabe, H., Suzuki, T. (2009). Evaluation of Hepatitis C Virus Core Antigen Assays in Detecting Recombinant Viral Antigens of Various Genotypes. J. Clin. Microbiol. 47: 4141-4143 [Abstract] [Full Text]  
  • Sansonno, D., Tucci, F. A., Ghebrehiwet, B., Lauletta, G., Peerschke, E. I. B., Conteduca, V., Russi, S., Gatti, P., Sansonno, L., Dammacco, F. (2009). Role of the Receptor for the Globular Domain of C1q Protein in the Pathogenesis of Hepatitis C Virus-Related Cryoglobulin Vascular Damage. J. Immunol. 183: 6013-6020 [Abstract] [Full Text]  
  • Hara, H., Aizaki, H., Matsuda, M., Shinkai-Ouchi, F., Inoue, Y., Murakami, K., Shoji, I., Kawakami, H., Matsuura, Y., Lai, M. M. C., Miyamura, T., Wakita, T., Suzuki, T. (2009). Involvement of Creatine Kinase B in Hepatitis C Virus Genome Replication through Interaction with the Viral NS4A Protein. J. Virol. 83: 5137-5147 [Abstract] [Full Text]  
  • Kato, T., Matsumura, T., Heller, T., Saito, S., Sapp, R. K., Murthy, K., Wakita, T., Liang, T. J. (2007). Production of Infectious Hepatitis C Virus of Various Genotypes in Cell Cultures. J. Virol. 81: 4405-4411 [Abstract] [Full Text]  
  • Miyamoto, H., Moriishi, K., Moriya, K., Murata, S., Tanaka, K., Suzuki, T., Miyamura, T., Koike, K., Matsuura, Y. (2007). Involvement of the PA28{gamma}-Dependent Pathway in Insulin Resistance Induced by Hepatitis C Virus Core Protein. J. Virol. 81: 1727-1735 [Abstract] [Full Text]  
  • Moriishi, K., Mochizuki, R., Moriya, K., Miyamoto, H., Mori, Y., Abe, T., Murata, S., Tanaka, K., Miyamura, T., Suzuki, T., Koike, K., Matsuura, Y. (2007). Critical role of PA28{gamma} in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc. Natl. Acad. Sci. USA 104: 1661-1666 [Abstract] [Full Text]  
  • Nakai, K., Okamoto, T., Kimura-Someya, T., Ishii, K., Lim, C. K., Tani, H., Matsuo, E., Abe, T., Mori, Y., Suzuki, T., Miyamura, T., Nunberg, J. H., Moriishi, K., Matsuura, Y. (2006). Oligomerization of Hepatitis C Virus Core Protein Is Crucial for Interaction with the Cytoplasmic Domain of E1 Envelope Protein. J. Virol. 80: 11265-11273 [Abstract] [Full Text]  
  • Takahashi, M., Saito, H., Higashimoto, M., Atsukawa, K., Ishii, H. (2005). Benefit of Hepatitis C Virus Core Antigen Assay in Prediction of Therapeutic Response to Interferon and Ribavirin Combination Therapy. J. Clin. Microbiol. 43: 186-191 [Abstract] [Full Text]  
  • Fabrizi, F., Lunghi, G., Aucella, F., Mangano, S., Barbisoni, F., Bisegna, S., Vigilante, D., Limido, A., Martin, P. (2005). Novel Assay Using Total Hepatitis C Virus (HCV) Core Antigen quantification for Diagnosis of HCV Infection in Dialysis Patients. J. Clin. Microbiol. 43: 414-420 [Abstract] [Full Text]  
  • Kawaguchi, T., Yoshida, T., Harada, M., Hisamoto, T., Nagao, Y., Ide, T., Taniguchi, E., Kumemura, H., Hanada, S., Maeyama, M., Baba, S., Koga, H., Kumashiro, R., Ueno, T., Ogata, H., Yoshimura, A., Sata, M. (2004). Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3. Am. J. Pathol. 165: 1499-1508 [Abstract] [Full Text]  
  • Nielsen, S. U., Bassendine, M. F., Burt, A. D., Bevitt, D. J., Toms, G. L. (2004). Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J. Gen. Virol. 85: 1497-1507 [Abstract] [Full Text]  
  • Moriishi, K., Okabayashi, T., Nakai, K., Moriya, K., Koike, K., Murata, S., Chiba, T., Tanaka, K., Suzuki, R., Suzuki, T., Miyamura, T., Matsuura, Y. (2003). Proteasome Activator PA28{gamma}-Dependent Nuclear Retention and Degradation of Hepatitis C Virus Core Protein. J. Virol. 77: 10237-10249 [Abstract] [Full Text]  
  • Veillon, P., Payan, C., Picchio, G., Maniez-Montreuil, M., Guntz, P., Lunel, F. (2003). Comparative Evaluation of the Total Hepatitis C Virus Core Antigen, Branched-DNA, and Amplicor Monitor Assays in Determining Viremia for Patients with Chronic Hepatitis C during Interferon Plus Ribavirin Combination Therapy. J. Clin. Microbiol. 41: 3212-3220 [Abstract] [Full Text]  
  • Kimura, T., Rokuhara, A., Matsumoto, A., Yagi, S., Tanaka, E., Kiyosawa, K., Maki, N. (2003). New Enzyme Immunoassay for Detection of Hepatitis B Virus Core Antigen (HBcAg) and Relation between Levels of HBcAg and HBV DNA. J. Clin. Microbiol. 41: 1901-1906 [Abstract] [Full Text]  
  • Lagging, L. M., Garcia, C. E., Westin, J., Wejstal, R., Norkrans, G., Dhillon, A. P., Lindh, M. (2002). Comparison of Serum Hepatitis C Virus RNA and Core Antigen Concentrations and Determination of Whether Levels Are Associated with Liver Histology or Affected by Specimen Storage Time. J. Clin. Microbiol. 40: 4224-4229 [Abstract] [Full Text]  
  • Kimura, T., Rokuhara, A., Sakamoto, Y., Yagi, S., Tanaka, E., Kiyosawa, K., Maki, N. (2002). Sensitive Enzyme Immunoassay for Hepatitis B Virus Core-Related Antigens and Their Correlation to Virus Load. J. Clin. Microbiol. 40: 439-445 [Abstract] [Full Text]  
  • PERLEMUTER, G., SABILE, A., LETTERON, P., VONA, G., TOPILCO, A., CHRETIEN, Y., KOIKE, K., PESSAYRE, D., CHAPMAN, J., BARBA, G., BRECHOT, C. (2002). Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 16: 185-194 [Abstract] [Full Text]  
  • Yao, Z. Q., Nguyen, D. T., Hiotellis, A. I., Hahn, Y. S. (2001). Hepatitis C Virus Core Protein Inhibits Human T Lymphocyte Responses by a Complement-Dependent Regulatory Pathway. J. Immunol. 167: 5264-5272 [Abstract] [Full Text]  
  • Maillard, P., Krawczynski, K., Nitkiewicz, J., Bronnert, C., Sidorkiewicz, M., Gounon, P., Dubuisson, J., Faure, G., Crainic, R., Budkowska, A. (2001). Nonenveloped Nucleocapsids of Hepatitis C Virus in the Serum of Infected Patients. J. Virol. 75: 8240-8250 [Abstract] [Full Text]  
  • Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., Seeff, L. B. (2000). Diagnosis and Monitoring of Hepatic Injury. I. Performance Characteristics of Laboratory Tests. Clin. Chem. 46: 2027-2049 [Abstract] [Full Text]